Загрузка...
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
AIMS: Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a novel anti‐CD20 monoclonal antibody with improved...
Сохранить в:
| Опубликовано в: : | Br J Clin Pharmacol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710522/ https://ncbi.nlm.nih.gov/pubmed/31050355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13974 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|